CN107653237A - 一种用于医学临床检验的采血管添加剂 - Google Patents

一种用于医学临床检验的采血管添加剂 Download PDF

Info

Publication number
CN107653237A
CN107653237A CN201711115422.3A CN201711115422A CN107653237A CN 107653237 A CN107653237 A CN 107653237A CN 201711115422 A CN201711115422 A CN 201711115422A CN 107653237 A CN107653237 A CN 107653237A
Authority
CN
China
Prior art keywords
complexing agent
heparin tube
parts
examined
metalloenzyme
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201711115422.3A
Other languages
English (en)
Inventor
王之侃
胡圆圆
金黄根
吴向阳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ANHUI SINIC LABORATORY MEDICINE TECHNOLOGY Co Ltd
Original Assignee
ANHUI SINIC LABORATORY MEDICINE TECHNOLOGY Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ANHUI SINIC LABORATORY MEDICINE TECHNOLOGY Co Ltd filed Critical ANHUI SINIC LABORATORY MEDICINE TECHNOLOGY Co Ltd
Priority to CN201711115422.3A priority Critical patent/CN107653237A/zh
Publication of CN107653237A publication Critical patent/CN107653237A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/99—Enzyme inactivation by chemical treatment
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
    • B05D—PROCESSES FOR APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
    • B05D1/00—Processes for applying liquids or other fluent materials
    • B05D1/02—Processes for applying liquids or other fluent materials performed by spraying
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
    • B05D—PROCESSES FOR APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
    • B05D3/00—Pretreatment of surfaces to which liquids or other fluent materials are to be applied; After-treatment of applied coatings, e.g. intermediate treating of an applied coating preparatory to subsequent applications of liquids or other fluent materials
    • B05D3/04—Pretreatment of surfaces to which liquids or other fluent materials are to be applied; After-treatment of applied coatings, e.g. intermediate treating of an applied coating preparatory to subsequent applications of liquids or other fluent materials by exposure to gases
    • B05D3/0406—Pretreatment of surfaces to which liquids or other fluent materials are to be applied; After-treatment of applied coatings, e.g. intermediate treating of an applied coating preparatory to subsequent applications of liquids or other fluent materials by exposure to gases the gas being air
    • B05D3/0413—Heating with air
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/75—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
    • G01N21/76—Chemiluminescence; Bioluminescence
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/75—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
    • G01N21/76—Chemiluminescence; Bioluminescence
    • G01N21/763—Bioluminescence
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/66—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Plasma & Fusion (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明涉及一种用于医学临床检验的采血管添加剂所述的采血管添加剂为血液酶转抑制剂，由羟胺络合剂和金属酶离子络合剂组成，所述的金属酶离子络合剂为含阴离表面活性剂的低离子介质，其PH为7.0±0.2。采血管的制备方法如下:利用采血管自动生产线上定量喷头将氨羟络合剂从硅化好的采血管管口自上而下喷涂至距管底2厘米处结束；将己喷涂氨羟络合剂的采血管管身、利用生产线上的热空气喷头、喷热气流烘干，再用生产线上的另一组定量喷头，自采血管管底部定量注入金属酶离子络合剂；进入采血管下道工序生产环节：预置真空度、热合、包装入库。本发明的采血管用于医学临床检验中高血压病糖尿病检测的结果更加接近人体原值。

Description

一种用于医学临床检验的采血管添加剂
技术领域
本发明涉及医疗器械技术领域，具体涉及一种用于医学临床检验的采血管添加剂。
背景技术
在常规采血管采血后，检测前的温浴、离心等标本前处理的过程中，血液中的血管紧张素转化酶，糖酵解的磷酸烯醇转化酶仍然具有酶活力，会促进底物如：血管紧张素转化为醛固酮等不同分子的代谢产物，糖酵转为乳酸等，从而导致血液中的血管紧张素、肾素、醛固酮相互转变或血糖测定结果不同程度的降低。尤其是在临床高血压、糖尿病检验过程中，每位患者血液中血管紧张素转化酶、糖酵解磷酸烯醇转化酶的含量和活性都不同，直接使用现有技术中的采血管会使测定物质血管紧张素、血糖的含量有不同程度的变化，不能出体内血液中原值；也无法进行结果数值经验概算评价；大概率降低了测定结果的临床意义。
目前抑制或灭活酶的方法有物理方法：温度、射线、超声波等；免疫方法：特异性单克隆抗体结合后改变酶中心构象，封闭酶功能团。但实际工作中成本太高，贮存条件严格，不适合低值耗材的生产和使用。同时，物理方法要对含于血液中的蛋白质性质的酶选择性的抑制或灭活，几乎无法做到。
发明内容
本发明的目的在于：提供一种适用高血压病、糖尿病检测项目釆血管添加剂，能够抑制血液中金属酶、血管紧张素转化酶、磷酸烯醇转化酶活性。
为了实现上述发明目的，本发明提供如下技术方案:
一种用于医学临床检验的采血管添加剂：所述的采血管添加剂为血液酶转抑制剂，由羟胺络合剂和金属酶离子络合剂组成，所述的金属酶离子络合剂为含阴离表面活性剂的低离子介质，其PH为7.0±0.2。
优选地，所述的金属酶离子络合剂由以下重量份的原料制备而成：羟基喹啉1.0-3.0份，疏基丙醇0.4-0.6份，吐温80：0.1-0.5份、Brij35：0.2-0.7份、水96-98份。
所述的金属酶离子络合剂的制备方法如下：将羟基喹啉、疏基丙醇，加水分别溶解、再加吐温80、Brij35、混匀、定容，制成金属酶离子络合剂；2-8℃冷藏备用。
优选地，所述的氨羟络合剂由以下重量份的原料制备而成：乙二胺四乙酸盐18-20份，二乙烯三胺五羧酸盐2-4份，甘油醛4-6份，乙醇29-31份，氟化钠4-6份，水37-39份。
所述的氨羟络合剂的制备方法如下：
将乙二胺四乙酸盐，二乙烯三胺五羧酸盐，甘油醛，乙醇，氟化钠分别加水溶解、混合、定容，制成氨羟络合剂。
一种用于医学临床检验的采血管制备方法，血液酶转抑制剂中羟胺络合剂和金属离络合剂在反应前保持自己特定的反应体系，包括以下步骤：
(1)利用采血管生产线上定量喷头将氨羟络合剂从硅化好的采血管管口自上而下喷涂至距管底2厘米处结束；
(2)将己喷涂氨羟络合剂的采血管利用线上热空气喷头吹干，再利用采血管生产线上的另一组定量喷头，于采血管管底定量注入金属酶离子络合剂；
(3)进入采血管下道工序生产环节：预置真空度、热合、包装入库。
优选地，所述的血液酶转抑制剂的加入量与采血管的体积有关，1ml采血管加入的金属酶离子络合剂的量为2.2mg±10％；1ml采血管加入的氨羟络合剂的量为15ul±10％。
本发明的有益效果在于：本发明的血液金属酶抑制剂是一种由配方化剂形成特定的PH值、含阴离子表面活性剂的低离子介质血液金属酶络合剂。在(血液金属酶络合剂：血液为0.5：4.5的比例)反应体系中、血液内金属酶结构中心的金属离子被本发明血液金属酶络合剂被金属离子络合剂成不溶性螯合物，改变了酶的活性中心的结构和必需基团的活性。不可逆的抑制和降低酶转反应速度。转化酶血管紧张素转化酶、磷酸烯醇转化酶的活性降低或丧失。使高血疬检验项目：醛固酮、肾素、血管紧张素、糖尿病检验项目：血糖、在使用本发明的采血管釆集的血液检验结果更加接近体内真值。
具体实施方式
实施例1：
一种用于医学临床检验的采血管添加剂，所述的采血管添加剂为血液酶转抑制剂，由羟胺络合剂和金属酶离子络合剂组成，所述的金属酶离子络合剂为含阴离表面活性剂的低离子介质，其PH为7.0±0.2。
其中，所述的氨羟络合剂由以下重量份的原料制备而成：乙二胺四乙酸盐19份，二乙烯三胺五羧酸盐3份，甘油醛5份，乙醇30份，氟化钠5份，水38份，其制备方法为：将乙二胺四乙酸盐，二乙烯三胺五羧酸盐，甘油醛，乙醇，氟化钠分别加水溶解、混合、定容，制成氨羟络合剂。
所述的金属酶离子络合剂由以下重量份的原料制备而成：羟基喹啉2.5份，疏基丙醇0.5份，吐温80：0.1份，Brij35：0.2份水96.7份，其制备方法为:将羟基喹啉、疏基丙醇，加水分别溶解、再加吐温80、Brij35、混合、定容，制成金属酶离子络合剂。2-8℃冷藏备用。
实施例2:
一种用于医学临床检验的采血管制备方法，包括以下步骤：
(1)利用采血管生产线上定量喷头将氨羟络合剂从硅化好的采血管管口自上而下喷涂至距管底2厘米处结束；
(2)将巳喷涂氨羟络合在采血管生产线上热空气喷头吹干，再利用采血管生产线上的另一组定量喷头，自采血管管底定量注入金属酶离子络合剂；
(3)进入采血管下道工序生产环节：预置真空度、热合、包装入库。
实施例3：
随机在常规体检的自然人群中任选38例静脉采血两支(一支EDTA2K采血管，一支本发明制备的采血管)。三小时内用化学发光法测试：醛固酮、肾素、血管紧张素Ⅰ，用生化分析仪(已糖激酶HK法)测定血糖。结果如下：
从上述结果中可以看出：本发明的血液酶转络合抑制剂是一种复合金属离子，血液酶转络合抑制剂和血管紧张素转化酶、磷酸烯醇转化酶转不可逆产物，金属酶离子络合剂对血液的介质中金属离子和酶含金属离子络合成不溶性整合物，并改变了酶的活性中心的结构和必需基团的属性发生了改变。不可逆反应的酶转产物，抑制和降低酶转反应速度。使目标转化酶血管紧张素转化酶、磷酸烯醇转化酶的活性降低或丧失。所以，使用本发明的采血管使得血液的检测结果更加准确。

Claims (7)

1.一种用于医学临床检验的采血管添加剂：所述的采血管添加剂为血液酶转抑制剂，由羟胺络合剂和金属酶离子络合剂组成，其特征在于：所述的金属酶离子络合剂为含阴离表面活性剂的低离子介质，其PH为7.0±0.2。
2.根据权利要求1所述的用于医学临床检验的采血管添加剂，其特征在于：所述的金属酶离子络合剂由以下重量份的原料制备而成：羟基喹啉1.0-3.0份，疏基丙醇0.4-0.6份，吐温80：0.1-0.5份、Brij35：0.2-0.7份、水96-98份。
3.根据权利要求2所述的用于医学临床检验的采血管添加剂，其特征在于：所述的金属酶离子络合剂的制备方法如下：
将羟基喹啉、疏基丙醇，加水分别溶解、再加吐温80、Brij35、混匀、定容，制成金属酶离子络合剂；2-8℃冷藏备用。
4.根据权利要求1所述的用于医学临床检验的采血管添加剂，其特征在于：所述的氨羟络合剂由以下重量份的原料制备而成：乙二胺四乙酸盐18-20份，二乙烯三胺五羧酸盐2-4份，甘油醛4-6份，乙醇29-31份，氟化钠4-6份，水37-39份。
5.根据权利要求4所述的用于医学临床检验的采血管添加剂，其特征在于：所述的氨羟络合剂的制备方法如下：
将乙二胺四乙酸盐，二乙烯三胺五羧酸盐，甘油醛，乙醇，氟化钠分别加水溶解、混合、定容，制成氨羟络合剂。
6.一种用于医学临床检验的采血管制备方法，其特征在于：血液酶转抑制剂中羟胺络合剂和金属离络合剂在反应前保持自己特定的反应体系，包括以下步骤：
(1)利用采血管生产线上定量喷头将氨羟络合剂从硅化好的采血管管口自上而下喷涂至距管底2厘米处结束；
(2)将己喷涂氨羟络合剂的采血管利用线上热空气喷头吹干，再利用采血管生产线上的另一组定量喷头，于采血管管底定量注入金属酶离子络合剂；
(3)进入采血管下道工序生产环节：预置真空度、热合、包装入库。
7.根据权利要求6所述的用于医学临床检验的采血管制备方法，其特征在于：所述的血液酶转抑制剂的加入量与采血管的体积有关，1ml采血管加入的金属酶离子络合剂的量为2.2mg±10％；1ml采血管加入的氨羟络合剂的量为15ul±10％。
CN201711115422.3A 2017-11-13 2017-11-13 一种用于医学临床检验的采血管添加剂 Pending CN107653237A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201711115422.3A CN107653237A (zh) 2017-11-13 2017-11-13 一种用于医学临床检验的采血管添加剂

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201711115422.3A CN107653237A (zh) 2017-11-13 2017-11-13 一种用于医学临床检验的采血管添加剂

Publications (1)

Publication Number Publication Date
CN107653237A true CN107653237A (zh) 2018-02-02

Family

ID=61120352

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201711115422.3A Pending CN107653237A (zh) 2017-11-13 2017-11-13 一种用于医学临床检验的采血管添加剂

Country Status (1)

Country Link
CN (1) CN107653237A (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108893524A (zh) * 2018-06-04 2018-11-27 北京启衡星生物科技有限公司 血浆中游离dna的保护剂
CN115039760A (zh) * 2022-06-16 2022-09-13 郑州安图生物工程股份有限公司 缓冲基质液及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2910260A1 (en) * 2012-09-10 2015-08-26 Fenwal, Inc. Membrane separation devices, systems and methods employing same, and data management systems and methods
CN105286885A (zh) * 2015-09-17 2016-02-03 安徽信灵检验医学科技有限公司 一种用于医学临床检验的采血管及其制备方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2910260A1 (en) * 2012-09-10 2015-08-26 Fenwal, Inc. Membrane separation devices, systems and methods employing same, and data management systems and methods
CN105286885A (zh) * 2015-09-17 2016-02-03 安徽信灵检验医学科技有限公司 一种用于医学临床检验的采血管及其制备方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
王利霞: "真空采血管内添加物对常见生化项目测定结果的影响", 《亚太传统医学》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108893524A (zh) * 2018-06-04 2018-11-27 北京启衡星生物科技有限公司 血浆中游离dna的保护剂
CN115039760A (zh) * 2022-06-16 2022-09-13 郑州安图生物工程股份有限公司 缓冲基质液及其应用

Similar Documents

Publication Publication Date Title
Brackett Jr et al. Hyperplasia of the juxtaglomerular complex with secondary aldosteronism without hypertension (Bartter's syndrome)
CN107653237A (zh) 一种用于医学临床检验的采血管添加剂
CN104316692B (zh) 一种新生儿总半乳糖检测试剂盒、其使用方法及制备方法
CN105286885A (zh) 一种用于医学临床检验的采血管及其制备方法
CN103389383A (zh) 一种测定血清中肌红蛋白含量的检测试剂盒
CN106868096A (zh) 一种稳定性强且成本低的己糖激酶法葡萄糖检测试剂
CN109239374A (zh) 一种液体型凝血酶时间检测试剂
CN102532610B (zh) 一种病理包埋剂及其制备方法和应用
CN109001455A (zh) 一种肺泡灌洗液样本处理液及处理检测方法
CN116445419B (zh) 11dhTxB2单克隆抗体及其制备方法和应用
CN105456280B (zh) 靶向于肌动蛋白结合蛋白Transgelin-2的化合物及其新用途
CN107132088B (zh) 把体液标本沉淀物即刻凝固的试剂
CN107884585B (zh) 缺氧诱导的有丝分裂因子的蛋白检测试剂盒及其应用
CN104849122A (zh) 一种长效肿瘤组织渗液样本保存液
CN101793799A (zh) 乳糖诊断/测定试剂(盒)及乳糖浓度测定方法
CN101793802A (zh) 乳糖诊断/测定试剂(盒)及乳糖浓度测定方法
CN104187786A (zh) 一种提高羊肉盐溶蛋白热凝胶硬度的方法
CN103616374A (zh) 糖尿病人的丙二醛的测定方法
CN101793783A (zh) 乳糖诊断/测定试剂(盒)及乳糖浓度测定方法
CN101169447A (zh) 亚铁离子诊断/测定试剂盒及亚铁离子的浓度测定方法
CN101793732A (zh) 乳糖诊断/测定试剂(盒)及乳糖浓度测定方法
CN101793811A (zh) 乳糖诊断/测定试剂(盒)及乳糖浓度测定方法
CN101793700A (zh) 乳糖诊断/测定试剂(盒)及乳糖浓度测定方法
CN101793776A (zh) 乳糖诊断/测定试剂(盒)及乳糖浓度测定方法
CN101793698A (zh) 乳糖诊断/测定试剂(盒)及乳糖浓度测定方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Address after: 231400 No. 2 Dongyibei Road, Tongcheng Economic Development Zone, Anqing City, Anhui Province

Applicant after: Anhui Xinling Laboratory Medicine Technology Co., Ltd.

Address before: 246000 Tongxiang Road, Tongcheng Economic Development Zone, Anqing City, Anhui Province

Applicant before: Anhui Sinic Laboratory Medicine Technology Co., Ltd.

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20180202